Picture EBD Group World of Partnering Opportunities 650x100px
Collaboration › Details

Twist Bioscience–JPMorgan Chase: investor conference, 202401 supply service Twist Bioscience presents at JP Morgan Healthcare Conference 2024


Period Period 2024-01-08
Region Region San Francisco, CA
  Country United States (USA)
  Predecessor Agilent–JPMorgan Chase: investor conference, 202301 supply service Agilent presents at JP Morgan Healthcare Conference 2023
Organisations Partner, 1st Twist Bioscience Corporation (Nasdaq: TWST)
  Group Twist Bioscience (Group)
  Partner, 2nd J.P. Morgan Securities LLC
  Group JPMorgan Chase (Group)
Products Product J.P. Morgan 42nd Annual Healthcare Conference 2024 San Francisco
  Product 2 synthetic biotechnology
Persons Person LeProust, Emily M. (Twist Bioscience 2013– CEO + Co-Founder before Agilent Director Genomics Application Development)
  Person 2 Bitting, Angela (Twist Bioscience 202002 Media Contact)

Twist Bioscience Corporation. (12/18/23). "Press Release: Twist Bioscience to Present at 42nd Annual J.P. Morgan Healthcare Conference". South San Francisco, CA.

Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8 at 5:15 p.m. Pacific Time in San Francisco, CA.

The presentation will be webcast live and can be accessed by visiting the “Investor Calendar” page of the investor relations section of the company's website here. A replay of the presentation will be archived for a period of 30 days following the conclusion of the live events.

About Twist Bioscience Corporation

Twist Bioscience is a leading and rapidly growing synthetic biology and genomics company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The core of the platform is a proprietary technology that pioneers a new method of manufacturing synthetic DNA by “writing” DNA on a silicon chip. Twist is leveraging its unique technology to manufacture a broad range of synthetic DNA-based products, including synthetic genes, tools for next-generation sequencing (NGS) preparation, and antibody libraries for drug discovery and development. Twist is also pursuing longer-term opportunities in digital data storage in DNA and biologics drug discovery. Twist makes products for use across many industries including healthcare, industrial chemicals, agriculture and academic research.

Follow us on Twitter | Facebook | LinkedIn | YouTube

For Investors:

Angela Bitting
SVP, Corporate Affairs

For Media:

Amanda Houlihan
Communications Generalist

Record changed: 2023-12-18


Picture Demy-Colton BioFuture 2024 NYC 3 Healthcare Revolution 650x200px

More documents for Twist Bioscience (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture Demy-Colton BioFuture 2024 NYC Game Changers 650x300px

» top